Literature DB >> 3582422

Pharmacokinetics of chloroquine: saliva and plasma levels relationship.

E I Ette, E E Essien, E E Brown-Awala.   

Abstract

The use of saliva levels as an alternative to plasma levels in monitoring chloroquine therapy was studied in five healthy volunteers. Subjects took two (250 mg) tablets of chloroquine diphosphate (300 mg chloroquine base) with 200 ml of water. Saliva and blood samples were collected at intervals over 6 days. Plasma was separated from blood samples after centrifugation while saliva samples were centrifuged to remove mucoid sediments. Both the plasma and saliva samples were analysed for chloroquine by a combination of thin-layer chromatography and spectrophotometry. Regression analysis was used to determine the correlation between saliva and plasma chloroquine levels. A significant correlation (r = 0.97, p less than 0.05) was observed between saliva and plasma levels of chloroquine. The saliva: plasma concentrations ratio was found to be 0.53. From the saliva: plasma relationship, the extent of chloroquine binding to plasma proteins was estimated to be 47%. The Cmax and AUC0-6 day values obtained from saliva data was about half those from plasma, while the Tmax obtained from both fluids remained the same. The saliva clearance rate (Cls/F) of chloroquine was about twice the plasma clearance rate (Cl/F). (Cls/F: 0.46 +/- 0.051/day/kg; 0.27 +/- 0.021/day/kg). However, the predicted Cl/F (0.27 +/- 0.031/day/kg) from saliva data was in agreement with Cl/F from plasma data. This was also true of the volume of distribution. The collection of saliva for measuring chloroquine levels provides a painless, non-invasive alternative to plasma sampling, and it is useful in predicting chloroquine pharmacokinetics.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3582422     DOI: 10.1007/BF03189112

Source DB:  PubMed          Journal:  Eur J Drug Metab Pharmacokinet        ISSN: 0378-7966            Impact factor:   2.441


  16 in total

1.  The permeability of the human parotid gland to a series of sulfonamide compounds, para-aminohippurate and inulin.

Authors:  S A KILLMANN; J H THAYSEN
Journal:  Scand J Clin Lab Invest       Date:  1955       Impact factor: 1.713

2.  STUDIES ON THE CHEMOTHERAPY OF THE HUMAN MALARIAS. VI. THE PHYSIOLOGICAL DISPOSITION, ANTIMALARIAL ACTIVITY, AND TOXICITY OF SEVERAL DERIVATIVES OF 4-AMINOQUINOLINE.

Authors:  R W Berliner; D P Earle; J V Taggart; C G Zubrod; W J Welch; N J Conan; E Bauman; S T Scudder; J A Shannon
Journal:  J Clin Invest       Date:  1948-05       Impact factor: 14.808

3.  Pharmacokinetics of tolbutamide: prediction by concentration in saliva.

Authors:  S B Matin; S H Wan; J H Karam
Journal:  Clin Pharmacol Ther       Date:  1974-12       Impact factor: 6.875

4.  The effects of acute chloroquine poisoning with special reference to the heart.

Authors:  T A Don Michael; S Aiwazzadeh
Journal:  Am Heart J       Date:  1970-06       Impact factor: 4.749

5.  Residual chloroquine and metabolites in man as a sequel of previous chloroquine medications: a urinary excretion study and its significance.

Authors:  E E Essien; N D Ifudu
Journal:  J Trop Med Hyg       Date:  1984-06

6.  Complete heart block due to chronic chloroquine toxicity managed with permanent pacemaker.

Authors:  A C Edwards; T J Meredith; E Sowton
Journal:  Br Med J       Date:  1978-04-29

7.  The binding of chloroquine to normal and Kwashiorkor serum.

Authors:  N Buchanan; L A Van der Walt
Journal:  Am J Trop Med Hyg       Date:  1977-09       Impact factor: 2.345

8.  Salivary excretion of paracetamol in man.

Authors:  J P Glynn; W Bastain
Journal:  J Pharm Pharmacol       Date:  1973-05       Impact factor: 3.765

9.  Chloroquine serum concentration and side effects: evidence for dose-dependent kinetics.

Authors:  M Frisk-Holmberg; Y Bergkvist; B Domeij-Nyberg; L Hellström; F Jansson
Journal:  Clin Pharmacol Ther       Date:  1979-03       Impact factor: 6.875

10.  Application of salivary salicylate data to biopharmaceutical studies of salicylates.

Authors:  G Graham; M Rowland
Journal:  J Pharm Sci       Date:  1972-08       Impact factor: 3.534

View more
  5 in total

1.  Time-dependent variability of chloroquine secretion into human saliva.

Authors:  C O Onyeji; F A Ogunbona
Journal:  Pharm World Sci       Date:  1996-12

Review 2.  Antimalarial agents: specific chemoprophylaxis regimens.

Authors:  B L Herwaldt; D J Krogstad; P H Schlesinger
Journal:  Antimicrob Agents Chemother       Date:  1988-07       Impact factor: 5.191

Review 3.  Pharmacokinetics of quinine, chloroquine and amodiaquine. Clinical implications.

Authors:  S Krishna; N J White
Journal:  Clin Pharmacokinet       Date:  1996-04       Impact factor: 6.447

Review 4.  Clinical pharmacokinetics of slow-acting antirheumatic drugs.

Authors:  S E Tett
Journal:  Clin Pharmacokinet       Date:  1993-11       Impact factor: 6.447

5.  A high performance liquid chromatographic assay of mefloquine in saliva after a single oral dose in healthy adult Africans.

Authors:  Grace O Gbotosho; Christian T Happi; Omowunmi Lawal; Abayomi Sijuade; Akin Sowunmi; Ayoade Oduola
Journal:  Malar J       Date:  2012-02-27       Impact factor: 2.979

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.